AMYGDALA NEUROSCIENCE
Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use disorder. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse. In pre-clinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin,... methamphetamine and binge eating models and also demonstrated anxiolytic properties in models of stress. ANS-6637 has completed extensive Phase 1 studies and is ready for Phase 2 efficacy studies. Their initial development focus is for smoking cessation with parallel development efforts for cocaine, opioid and alcohol use disorders.
AMYGDALA NEUROSCIENCE
Social Links:
Industry:
Biotechnology Health Care Neuroscience Online Portals Pharmaceutical
Founded:
2015-01-01
Address:
Palo Alto, California, United States
Country:
United States
Website Url:
http://www.amygns.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
6.95 M USD
Technology used in webpage:
Google Universal Analytics AJAX Libraries API Apple Whitelist Google Translate Widget Zendesk Embeddables Zendesk Dropbox Tiny MCE Constant Contact Ooyala
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Apic Bio
Apic Bio is a gene therapy company that develops treatment options for rare, undertreated neurological and liver diseases.
Atlas Venture
Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
EnBiotix
EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
FORMA Therapeutics
FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.
humm
humm harnesses cutting-edge neuroscience into products that allow people to learn faster and perform better.
NuChem Sciences
NuChem Sciences is a drug discovery in chemistry contract research organization (CRO) located in Montréal and Lévis.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Employees Featured
Founder
Investors List
U.S. Department of Defense
U.S. Department of Defense investment in Series A - Amygdala Neuroscience
National Institutes of Health
National Institutes of Health investment in Series A - Amygdala Neuroscience
National Institutes of Health
National Institutes of Health investment in Grant - Amygdala Neuroscience
Asset Management Ventures (AMV)
Asset Management Ventures (AMV) investment in Seed Round - Amygdala Neuroscience
Asset Management Ventures (AMV)
Asset Management Ventures (AMV) investment in Venture Round - Amygdala Neuroscience
Official Site Inspections
http://www.amygns.com
- Host name: 186.221.184.35.bc.googleusercontent.com
- IP address: 35.184.221.186
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Amygdala Neuroscience"
About Us - Amygdala Neusciences
Our Story Amygdala Neurosciences, headquartered in San Francisco, CA, is an independent small biopharmaceutical company founded in 2015 whose mission is to address the growing …See details»
Home - Amygdala Neusciences
Addiction is a treatable recurring chronic disease. Amygdala Neurosciences is a biopharmaceutical company whose mission is to invent and develop first-in-class medicines to treat substance use disorders (SUD). Learn More Leading the …See details»
Amygdala Neuroscience - Crunchbase Company Profile …
Contact Email [email protected] Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use …See details»
Amygdala Neurosciences Inc | LinkedIn
Amygdala Neurosciences Inc is a biopahrmaceutical company whose mission is to invent and develop first-in-class medicines to treat substance use disorders (SUD ...See details»
Amygdala Neurosciences Inc Overview | SignalHire Company Profile
Organization Website. amygns.com . Amygdala Neuroscienc... industries. Biotech Headquarters Location. 509 HALE ST, Palo Alto, California, 94301 US. Amygdala Neuroscienc... Employees …See details»
ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 …
Philanthropic organization dedicated to the development and dissemination of new knowledge about the biological, behavioral and social aspects of alcohol consumption. Since that time, it …See details»
Amygdala Neurosciences - Products, Competitors, Financials, …
Headquarters Location. 509 Hale Street . San Francisco, California, 94301, United States. 650-714-0553See details»
Amygdala Neurosciences, Inc. (Amygdala …
Www.amygns.com. 更新于：2025-03-08. ... The Foundation was established in 1982 as an independent philanthropic organization dedicated to the development and dissemination of new knowledge about the biological, behavioral and …See details»
Amygdala Neuroscience Careers - Levels.fyi
Amygdala Neurosciences is a biopharmaceutical company based in California. They specialize in discovering and developing drugs for addiction disorders, catering to the healthcare industry.See details»
Amygdala Neurosciences Inc | | Amygdala Neurosciences Inc
Duns: 87878535: Cage Code: 7W4G8: Sam Extract Code: A: Purpose Of Registration: Z1: Initial Registration Date: 2017-06-20: Expiration Date: 2021-01-19: Last Update DateSee details»
Overview, News & Similar companies - ZoomInfo.com
Www.amygns.com. Revenue <$5 Million. Industry Drug Stores & Pharmacies Retail . Recent News & Media. Amygdala Neurosciences Awarded $2.0 million NIH Grant to Con... Aug 1, …See details»
Amygdala Neuroscience:Company Profile & Technical …
Amygdala Neuroscience is a company that provides Neuroscience, Health care and more. Amygdala Neuroscience is headquartered in United States California.See details»
Brent Blackburn - Amygdala Neurosciences Inc - LinkedIn
Brent Blackburn, PhD, is presently the CEO of Amygdala Neurosciences, a biopharmaceutical… · Experience: Amygdala Neurosciences Inc · Location: Los Altos · 500+ connections on …See details»
News - Amygdala Neusciences
Mar 28, 2019 May 14, 2024 | Amygdala Neursciences and ABMRF. ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder. Amygdala …See details»
ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 …
May 14, 2024 ABMRF/The Foundation for Alcohol Research was established in 1982 as an independent philanthropic organization dedicated to the development and dissemination of …See details»
Amygdala Neurosciences Announces Dosing the First Patients in …
SAN FRANCISCO, March 28, 2019 /PRNewswire/ -- Amygdala Neurosciences (a private company) announced today the start of dosing in a NIH/NIAID Phase 1b study to test the …See details»
Amygdala Neurosciences Awarded $1.35 million NIH Grant to
SAN FRANCISCO, Oct. 21, 2019 /PRNewswire/ -- Amygdala Neurosciences (a private company) has been awarded up to $1.35 million NIH grant support for the project titled “26- & 39-Week …See details»
Product Pipeline - Amygdala Neusciences
Our Compound We invented a compound, ANS-858, which is an orally bioavailable, selective, reversible ALDH2 inhibitor. Currently, ANS-858 is in preclinical development. ANS-858 was …See details»
Privacy Policy - Amygdala Neusciences - amygns.com
You may update, correct, or delete information about you at any time by emailing us at [email protected]. Note that we may retain certain information as required by law or for …See details»
Amygdala Neurosciences Announces Dosing the First Patients in …
Apr 2, 2019 For further Information, visit www.amygns.com or contact [email protected]. The content is solely the responsibility of the authors and does not necessarily represent the …See details»